title: Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
authors.forename: Gen-Min
authors.initials: GM
authors.lastname: Lin
authors.forename: Yi-Hwei
authors.initials: YH
authors.lastname: Li
authors.forename: Lamin E S
authors.initials: LE
authors.lastname: Jaiteh
authors.forename: Chih-Lu
authors.initials: CL
authors.lastname: Han
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015938:Complement Membrane Attack Complex / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000628:therapy*; D057127:Single-Chain Antibodies / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015938:Complement Membrane Attack Complex; D057127:Single-Chain Antibodies